208 related articles for article (PubMed ID: 30323548)
1. A Phase II/III, randomized, double-masked, vehicle-controlled, dose-ranging study of the safety and efficacy of OTX-101 in the treatment of dry eye disease.
Tauber J; Schechter BA; Bacharach J; Toyos MM; Smyth-Medina R; Weiss SL; Luchs JI
Clin Ophthalmol; 2018; 12():1921-1929. PubMed ID: 30323548
[TBL] [Abstract][Full Text] [Related]
2. A Phase 3, Randomized, Double-Masked Study of OTX-101 Ophthalmic Solution 0.09% in the Treatment of Dry Eye Disease.
Goldberg DF; Malhotra RP; Schechter BA; Justice A; Weiss SL; Sheppard JD
Ophthalmology; 2019 Sep; 126(9):1230-1237. PubMed ID: 30965064
[TBL] [Abstract][Full Text] [Related]
3. Lifitegrast Ophthalmic Solution 5.0% versus Placebo for Treatment of Dry Eye Disease: Results of the Randomized Phase III OPUS-2 Study.
Tauber J; Karpecki P; Latkany R; Luchs J; Martel J; Sall K; Raychaudhuri A; Smith V; Semba CP;
Ophthalmology; 2015 Dec; 122(12):2423-31. PubMed ID: 26365210
[TBL] [Abstract][Full Text] [Related]
4. Effect of OTX-101 in Patients with Dry Eye Disease at Day 14 of Treatment: Ocular Surface Endpoint Results from the Phase 2b/3 Clinical Trial.
Schechter BA; Urbieta M; Bacharach J; Toyos M; Smyth-Medina R; Mitchell B; Luchs JI
Clin Ophthalmol; 2022; 16():4145-4151. PubMed ID: 36536927
[TBL] [Abstract][Full Text] [Related]
5. The Effect of OTX-101 on Tear Production in Patients with Severe Tear-deficient Dry Eye Disease: A Pooled Analysis of Phase 2b/3 and Phase 3 Studies.
Toyos M; Gupta PK; Mitchell B; Karpecki P
Curr Eye Res; 2022 Feb; 47(2):220-224. PubMed ID: 34459350
[TBL] [Abstract][Full Text] [Related]
6. A Phase 2 Trial to Test Safety and Efficacy of ST-100, a Unique Collagen Mimetic Peptide Ophthalmic Solution for Dry Eye Disease.
Baratta RO; Schlumpf E; Del Buono BJ; DeLorey S; Ousler G; Calkins DJ
Ophthalmol Sci; 2024; 4(3):100451. PubMed ID: 38317866
[TBL] [Abstract][Full Text] [Related]
7. A Clinical Phase II Study to Assess Efficacy, Safety, and Tolerability of Waterfree Cyclosporine Formulation for Treatment of Dry Eye Disease.
Wirta DL; Torkildsen GL; Moreira HR; Lonsdale JD; Ciolino JB; Jentsch G; Beckert M; Ousler GW; Steven P; Krösser S
Ophthalmology; 2019 Jun; 126(6):792-800. PubMed ID: 30703441
[TBL] [Abstract][Full Text] [Related]
8. Lifitegrast ophthalmic solution 5.0% for treatment of dry eye disease: results of the OPUS-1 phase 3 study.
Sheppard JD; Torkildsen GL; Lonsdale JD; D'Ambrosio FA; McLaurin EB; Eiferman RA; Kennedy KS; Semba CP;
Ophthalmology; 2014 Feb; 121(2):475-83. PubMed ID: 24289915
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and Safety of OTX-101, a Novel Nanomicellar Formulation of Cyclosporine A, for the Treatment of Keratoconjunctivitis Sicca: Pooled Analysis of a Phase 2b/3 and Phase 3 Study.
Sheppard J; Kannarr S; Luchs J; Malhotra R; Justice A; Ogundele A; Darby C; Bacharach J
Eye Contact Lens; 2020 Jan; 46 Suppl 1():S14-S19. PubMed ID: 31361655
[TBL] [Abstract][Full Text] [Related]
10. Effect of OTX-101, a Novel Nanomicellar Formulation of Cyclosporine A, on Conjunctival Staining in Patients with Keratoconjunctivitis Sicca: A Pooled Analysis of Phase 2b/3 and 3 Clinical Trials.
Smyth-Medina R; Johnston J; Devries DK; Jasper A; Kannarr SR; Schechter BA; Shen Lee B; Varghese G; Ogundele A; Darby CH; Karpecki P; Luchs J
J Ocul Pharmacol Ther; 2019 Sep; 35(7):388-394. PubMed ID: 31373837
[No Abstract] [Full Text] [Related]
11. Phase 3 Efficacy (Worse-Eye Analysis) and Long-Term Safety Evaluation of OTX-101 in Patients with Keratoconjunctivitis Sicca.
Sheppard J; Bergmann M; Schechter BA; Luchs J; Ogundele A; Karpecki P
Clin Ophthalmol; 2021; 15():129-140. PubMed ID: 33469259
[TBL] [Abstract][Full Text] [Related]
12. Tofacitinib (CP-690,550), a Janus kinase inhibitor for dry eye disease: results from a phase 1/2 trial.
Liew SH; Nichols KK; Klamerus KJ; Li JZ; Zhang M; Foulks GN
Ophthalmology; 2012 Jul; 119(7):1328-35. PubMed ID: 22525048
[TBL] [Abstract][Full Text] [Related]
13. Rebamipide (OPC-12759) in the treatment of dry eye: a randomized, double-masked, multicenter, placebo-controlled phase II study.
Kinoshita S; Awamura S; Oshiden K; Nakamichi N; Suzuki H; Yokoi N;
Ophthalmology; 2012 Dec; 119(12):2471-8. PubMed ID: 23009892
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and Safety of a Water-Free Topical Cyclosporine, 0.1%, Solution for the Treatment of Moderate to Severe Dry Eye Disease: The ESSENCE-2 Randomized Clinical Trial.
Akpek EK; Wirta DL; Downing JE; Tauber J; Sheppard JD; Ciolino JB; Meides AS; Krösser S
JAMA Ophthalmol; 2023 May; 141(5):459-466. PubMed ID: 37022717
[TBL] [Abstract][Full Text] [Related]
15. A phase 2 randomized, double-masked, placebo-controlled study of novel nonsystemic kinase inhibitor TOP1630 for the treatment of dry eye disease.
Taylor M; Ousler G; Torkildsen G; Walshe C; Fyfe MCT; Rowley A; Webber S; Sheppard JD; Duggal A
Clin Ophthalmol; 2019; 13():261-275. PubMed ID: 30858682
[TBL] [Abstract][Full Text] [Related]
16. A Phase II, Multicenter, Randomized, Placebo-Controlled, Double-Masked Trial of a Topical Estradiol Ophthalmic Formulation in Postmenopausal Women with Moderate-to-Severe Dry Eye Disease.
Schmidl D; Szalai L; Kiss OG; Schmetterer L; Garhöfer G
Adv Ther; 2021 Apr; 38(4):1975-1986. PubMed ID: 33710587
[TBL] [Abstract][Full Text] [Related]
17. A Water-free 0.1% Cyclosporine A Solution for Treatment of Dry Eye Disease: Results of the Randomized Phase 2B/3 ESSENCE Study.
Sheppard JD; Wirta DL; McLaurin E; Boehmer BE; Ciolino JB; Meides AS; Schlüter T; Ousler GW; Usner D; Krösser S
Cornea; 2021 Oct; 40(10):1290-1297. PubMed ID: 34481407
[TBL] [Abstract][Full Text] [Related]
18. A Randomized Trial of Topical Fibrinogen-Depleted Human Platelet Lysate Treatment of Dry Eye Secondary to Chronic Graft-versus-Host Disease.
Sugar A; Hussain M; Chamberlain W; Dana R; Kelly DP; Ta C; Irvine J; Daluvoy M; Perez V; Olson J; Jhanji V; Walts TA; Stulting RD; Waller EK; Jagirdar N;
Ophthalmol Sci; 2022 Sep; 2(3):100176. PubMed ID: 36245754
[TBL] [Abstract][Full Text] [Related]
19. Cyclosporine A (0.05%) Ophthalmic Gel in the Treatment of Dry Eye Disease: A Multicenter, Randomized, Double-Masked, Phase III, COSMO Trial.
Peng W; Jiang X; Zhu L; Li X; Zhou Q; Jie Y; You Z; Wu M; Jin X; Li X; Zhou S
Drug Des Devel Ther; 2022; 16():3183-3194. PubMed ID: 36164414
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of 0.05% micellar nano-particulate (MNP) cyclosporine ophthalmic emulsion in the treatment of moderate-to-severe keratoconjunctivitis sicca: a 12-week, multicenter, randomized, active-controlled trial.
Rao AT; Gupta A; Chauhan T; Basu S; Batra N; Sharma N; Sangwan VS; Gupta V; Mukherjee S
BMC Ophthalmol; 2023 Mar; 23(1):121. PubMed ID: 36973703
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
